The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4356s-4359s

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

BREAST METASTASIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TAMOXIFEN;

EID: 0035661133     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fate of steroid estrogens in target tissues
2. The value of estrogen and progesterone receptors in the treatment of breast cancer
3. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors
4. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
5. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized doubleblind trial
6. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
7. Phase III, multicenter double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
8. Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
9. A phase III trial comparing vorozole (Rivizor) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer
10. Anastrozole is superior to tamoxifen in first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
11. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
12. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
13. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): Results of a randomized phase II trial
14. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (exemestane) in 1st line treatment of metastatic breast cancer: Companion study to a European Organization of Research and Treatment of Cancer Breast Group trial
15. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial